Press releasePRNewswire
Quest Diagnostics
DGX · NYSE
$237.12+$2.21 (+0.94%)TodayMarket closed ·
Prev close $234.91
Latest news
- Press releasePRNewswire
Current Screening Thresholds May Miss Half of Patients with Primary Aldosterone, a Leading Cause of Severe High Blood Pressure, Finds Study in Hypertension
- Press releasePRNewswire
Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
- Press releasePRNewswire
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
- NewsTanya Rawat
CMS Targets $1 Billion in Annual Savings With new Medicare Lab Payment Rates — Here’s What Could Change in 2027
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releasePRNewswire
Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
- Press releasePRNewswire
Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
- NewsPiero Cingari
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
- Press releasePRNewswire
Apple Health app Users to be Able to Order Labs from Quest Diagnostics
- Press releasePRNewswire
Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
- Press releasePRNewswire
Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com
- Press releasePRNewswire
Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
- Press releasePRNewswire
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
- Press releaseBusiness Wire
WHOOP Makes Advanced Labs Available Without a Wearable Membership
- Press releasePRNewswire
Quest Diagnostics Declares Quarterly Cash Dividend
- Press releasePRNewswire
Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics
- NewsVandana Singh
Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning
- NewsAvi Kapoor
Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday
- News
Transcript: Quest Diagnostics Q2 2026 Earnings Conference Call
- News
Earnings Scheduled For July 23, 2026
- News
Quest Diagnostics Q2 Adj. EPS $3.12 Beats $2.83 Estimate, Sales $3.043B Beat $2.973B Estimate
- Press releasePRNewswire
Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
- Press releasePRNewswire
One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns
- Press releasePRNewswire
Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI
- Press releasePRNewswire
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
- Press releasePRNewswire
UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics
- Press releasePRNewswire
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
- Press releasePRNewswire
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
- Press releasePRNewswire
Quest Diagnostics Declares Quarterly Cash Dividend
- Press releasePRNewswire
Quest Diagnostics Prices $500 Million of Senior Notes
- Press releasePRNewswire
Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
- Press releasePRNewswire
City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers
- Press releasePRNewswire
Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share
- Press releaseBusiness Wire
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
- NewsVandana Singh
Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing
- Press releasePRNewswire
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
- Press releasePRNewswire
Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index
- Press releasePRNewswire
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
- News
Quest Diagnostics Earnings Preview
- NewsVandana Singh
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
- Press releasePRNewswire
Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025
- Press releasePRNewswire
Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics
- Press releasePRNewswire
Investors Eye Biotech Sector as Cancer Therapy Market Surges
- Press releasePRNewswire
Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share
- Press releasePRNewswire
Quest Diagnostics Names Adrienne Brott Senior Vice President and Chief Quality and Regulatory Affairs Officer
- Press releasePRNewswire
Quest Diagnostics Reports Third Quarter 2024 Financial Results; Updates Guidance for Full Year 2024
- Press releasePRNewswire
Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.